CZIRR JAMES C
Known title: 10% OwnerCIK: 0001260641
Associated companies
Transaction History
| GALT | ▲ Buy | Option Exercise | 46,875 | $112K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 25,000 | $118K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 30,000 | $86K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 40,000 | $84K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 70,000 | $148K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 40,000 | $79K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 40,000 | $44K | 6/6/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 31,250 | $28K | 6/6/2025 | View on chart |
| GALT | ▼ Sell | Other | 1,000 | $6K | 3/31/2025 | View on chart |
| GALT | ▼ Sell | Gift | 10,000 | — | 2/4/2025 | View on chart |
| GALT | ▼ Sell | Gift | 10,000 | — | 2/3/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 3,677 | $11K | 4/23/2024 | View on chart |
| GALT | ▼ Sell | Open Market | 21,323 | $65K | 4/22/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.